Possibility and prospects of using bamlanivimab in patients with COVID-19
- Authors: Mirzaev K.B1, Sychev D.A1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 28, No 1 (2021)
- Pages: 17-19
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313052
- DOI: https://doi.org/10.18565/pharmateca.2021.1.17-19
- ID: 313052
Cite item
Open Access
Access granted
Abstract
Currently, there is insufficient scientific evidence to recommend the routine use of bamlanivimab for the treatment of outpatients with COVID-19. An interim analysis of the phase II randomized placebo-controlled BLAZE-1 trial demonstrates the potential clinical benefit of bamlanivimab for outpatients with mild to moderate COVID-19, and its effectiveness in preventing the development of COVID-19 among medical personnel and residents of nursing homes.
Keywords
Full Text
About the authors
K. B Mirzaev
Russian Medical Academy of Continuous Professional Education
D. A Sychev
Russian Medical Academy of Continuous Professional Education
References
- FDA News Release. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. Published November 9, 2020. (date of access: 22.12. 2020). URL: https://www.fda.gov/mvdia/143603/download
- Chen P, Nirula A., Heller B., et al; BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N EnglJ Med. Published on-line October 28, 2020. Doi: W.W56/NEJMoa202984-9.
- National Institutes of Health (NIH) News Release. Statement - NIH-sponsored ACTIV-3 trial closes LY-CoV555 sub-study. Published October 26, 2020. (date of access: 22.12.2020). URL: https://www.niaid.nih.gov/news-events/ statement-nih-sponsored-activ-3-trial-closes-ly-cov555-sub-study.
- URL: https://www.covid19treatmentgu'idelines. nih.gov/statement-on-bamlanivimab-eua
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (date of access: 28.12.2020). URL: https://www.idsociety.org/practice-guideline/ covid-19-guideline-treatment-and-management
Supplementary files
